Novel insights of disulfidptosis-mediated immune microenvironment regulation in atherosclerosis based on

Huanyi Zhao1, Zheng Jin1, Junlong Li1

  • 1First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.

Scientific Reports
|November 9, 2024
PubMed

Insights

Disulfidptosis, a novel cell death, is linked to atherosclerosis (AS). Four genes (CAPZB, DSTN, MYL6, PDLIM1) show diagnostic potential for AS and may guide immunotherapy strategies.

Area of Science:

  • Cardiovascular Biology
  • Cell Death Mechanisms
  • Bioinformatics

Background:

  • Atherosclerosis (AS) is a major cause of global mortality.
  • Disulfidptosis is an emerging cell death pathway with unclear roles in AS.
  • Understanding disulfidptosis in AS is crucial for developing new treatments.

Purpose of the Study:

  • To investigate the role of disulfidptosis in atherosclerosis.
  • To identify disulfidptosis-related genes as potential diagnostic markers for AS.
  • To explore the relationship between disulfidptosis subtypes and immune responses in AS.

Main Methods:

  • Bioinformatic analysis of AS datasets (GSE28829, GSE43292).
  • Identification of differentially expressed genes (DEGs) and hub genes using LASSO and Random Forests.
  • In vitro (foam cell model) and in vivo (AS mouse model) validation of hub genes.
  • Construction of a diagnostic nomogram and consensus clustering for AS subtypes.

Main Results:

  • Identified 9 disulfidptosis-related DEGs in AS.
  • Pinpointed 4 hub genes (CAPZB, DSTN, MYL6, PDLIM1) with diagnostic value for AS.
  • Validated hub gene expression in vitro and in vivo.
  • Developed a nomogram for accurate AS prediction.
  • Defined two disulfidptosis subtypes, with one showing increased immune cell infiltration.

Conclusions:

  • Disulfidptosis-related genes (CAPZB, DSTN, MYL6, PDLIM1) are potential diagnostic markers and therapeutic targets for AS.
  • These genes are linked to immune cells, suggesting a role in AS immunopathogenesis.
  • Findings may inform novel immunotherapy strategies for atherosclerosis.